

S1 Table. Clinicopathologic characteristics of pulmonary sarcomatoid carcinoma

Feature	Value
Age (yr)	68 (61-76)
Sex	
Male	25 (80.7)
Female	6 (16.7)
Smoking	
Never	8 (25.8)
Current	12 (38.7)
Ex-smoker	11 (35.5)
Tumor size (cm)	4.6 (3.8-5.6)
Pathologic diagnosis	
Pleomorphic carcinoma	28 (90.3)
Spindle cell carcinoma	2 (6.5)
Carcinosarcoma	1 (3.2)
Histologic subtype of carcinomatous area^{a)}	
Adenocarcinoma	20 (69.0)
Squamous cell carcinoma	6 (20.7)
Adenosquamous carcinoma	3 (10.3)
Histologic subtype of sarcomatous area	
Spindle cell	19 (61.3)
Giant cell	11 (35.5)
Chondrosarcoma	1 (3.2)
Pathologic stage	
1	5 (16.1)
2	13 (41.9)
3	11 (35.5)
4	2 (6.5)
Pleural invasion	
Present	18 (58.1)
Absent	13 (41.9)
Venous invasion	
Present	21 (67.7)
Absent	10 (32.3)
Lymphatic invasion	
Present	20 (67.7)
Absent	11 (32.3)
Neural invasion	
Present	5 (16.1)
Absent	26 (83.9)
<i>EGFR</i> mutation^{b)}	

Present	2 (11.8)
Absent	15 (88.2)
<i>KRAS</i> mutation^{b)}	
Present	2 (18.2)
Absent	9 (81.8)
Distant metastasis^{c)}	
Present	16 (51.6)
Absent	15 (48.4)
Disease progression	
Yes	17 (54.8)
No	14 (45.2)
Progression-free survival (mo)	9.00 (3.5-35.0)
Deceased	
Yes	17 (54.8)
No	14 (45.2)
Overall survival (mo)	24.0 (9.5-55.0)

Values are presented as median (IQR) or number (%). IQR, interquartile range; N, number of cases;

^{a)}Investigated only in biphasic primary pulmonary sarcomatoid carcinoma, ^{b)}Tested at the time of diagnosis, ^{c)}Metastasis to other sites than regional lymph nodes.